Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 13/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | SNCA | P37840 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20622695 | 0.89 | LPL (0.45) | LPLLIPGEGFRSNCAIRAK4 | |
| SCHEMBL19654842 | 0.84 | BACE1 (0.49) | LPLLIPGSNCAIRAK4 | |
| SCHEMBL30015879 | 0.84 | BACE1 (0.49) | LPLLIPGSNCAIRAK4 | |
| SCHEMBL12241754 | 0.83 | IRAK4 (0.49) | LPLLIPGEGFRSNCAIRAK4 | |
| SCHEMBL30453153 | 0.83 | IRAK4 (0.49) | LPLLIPGEGFRSNCAIRAK4 | |
| SCHEMBL20666276 | 0.81 | LPL (0.44) | LPLLIPGEGFRSNCAIRAK4 | |
| SCHEMBL30016092 | 0.81 | LPL (0.44) | LPLLIPGEGFRSNCAIRAK4 | |
| SCHEMBL20602523 | 0.80 | LPL (0.43) | LPLLIPGEGFRSNCAIRAK4 | |
| SCHEMBL29644319 | 0.79 | LPL (0.62) | LPLLIPGSNCAIRAK4CA1 | |
| SCHEMBL1293460 | 0.79 | LPL (0.62) | LPLLIPGSNCAIRAK4CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012123298-A1 | ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | WO | disclosed |
| US-20120230951-A1 | ANTIVIRAL COMPOUNDS | ALAM MUZAFFAR (US) | 2012-09-13 | — | — | US | disclosed |
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | PFIZER INC. | 2011-05-12 | — | — | US | disclosed |
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | PFIZER INC. | 2011-05-12 | — | — | US | disclosed |
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | PFIZER INC. | 2011-05-12 | — | — | US | disclosed |
| WO-2011004276-A1 | HEPATITIS C VIRUS INHIBITORS | PFIZER LIMITED (GB) | 2011-01-13 | — | — | WO | disclosed |
| WO-2011004276-A1 | HEPATITIS C VIRUS INHIBITORS | PFIZER LIMITED (GB) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | HAVCR2, SLC10A1, HCCS | LPL 2277/4885LIPG 1891/4885EGFR 1665/4885 |
| US-20120230951-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | LPL 954/4885LIPG 1168/4885EGFR 4020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.